1-(1-Benzothiophen-4-yl) Piperazinum Hydrochloridum CAS 913614-18-3 Puritas >98.0% (HPLC) Brexpiprazole Intermedia Factory

Description:

1-(1-Benzothiophen-4-yl) piperazinum hydrochloridum

CAS: 913614-18-3

Puritas: >99.0% (HPLC)

Aspectus: Alba ad Off-White pulveris

Medium Brexpiprazole (CAS: 913611-97-9)

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum 1-(1-Benzothiophen-4-yl) piperazinum hydrochloridum
Synonyma Brexpiprazole Medium 2;1-Benzo[b]thien-4-yl-Piperazinum hydrochloridum;1-Benzo[b]thien-4-ylpiperazinum Monohydrochloride
CAS Number 913614-18-3
CATTUS Number RF-PI1034
Stock Status In Stock, Productio Capacitas 100MT/Annus
Formulae hypotheticae C12H15ClN2S
M. Pondus 254.7789
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Alba ad Off-White pulveris
Lepidium sativum Retentione temporis specimen conforme est illi relationis vexillum
Puritas / Analysis Methodus >99.0% (HPLC)
Damnum in Siccatio <0.50%
Aquae (KF) <0.50%
Residere in Ignition <0.20%
Substantiae cognatae (HPLC)
Omnis immunditia <0.50%
Totalis immunditias <1.00%
Infrared Imaginis Conformat ut Structure
Proton NMR Spectrum Conformat ut Structure
Test Standard Enterprise Standard
Consuetudinem Medium Brexpiprazole (CAS: 913611-97-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

1

FAQ:

Applicatio:

1-(1-Benzothiophen-4-yl)piperazinum hydrochloridum (CAS: 913614-18-3) medium est Brexpiprazole (CAS: 913611-97-9).Brexpiprazole est genus atypicum antipsychoticum.Est dopamine D2 receptor partialis agonist.Cum nova actio modulatoris serotonin-dopamine, adhiberi potest ad tractationem schizophreniae et adiunctiva curatio pro tristitia.Praebere etiam potest efficaciam et tolerabilitatem in curationibus adiunctivis statutis inordinatio depressiva formajor (MDD).Medicamentum exhibet singularem profanum pharmacologicum, agonista serotonin 5-HT1A et dopamine receptorum 5-HT1A et tamquam plenus adversariorum receptorum 5-HT2A et noradrenalini α1B/2C, cum simili ligatura affinitatis subnanomolaris.Medicamentum, quod ab Otsuka et Lundbeck evolvit, anno 2015 ab FDA probatum est ad schizophreniae curationem et adiunctivam curationem pro tristitia.

Epistulam tuam hic scribe et mitte nobis